BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giri S, Nieber K, Bader A. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages. Expert Opinion on Drug Metabolism & Toxicology 2010;6:895-917. [DOI: 10.1517/17425251003792521] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Xia L, Sakban RB, Qu Y, Hong X, Zhang W, Nugraha B, Tong WH, Ananthanarayanan A, Zheng B, Chau IY, Jia R, McMillian M, Silva J, Dallas S, Yu H. Tethered spheroids as an in vitro hepatocyte model for drug safety screening. Biomaterials 2012;33:2165-76. [PMID: 22189144 DOI: 10.1016/j.biomaterials.2011.12.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
2 Meyer K, Ostrenko O, Bourantas G, Morales-Navarrete H, Porat-Shliom N, Segovia-Miranda F, Nonaka H, Ghaemi A, Verbavatz JM, Brusch L, Sbalzarini I, Kalaidzidis Y, Weigert R, Zerial M. A Predictive 3D Multi-Scale Model of Biliary Fluid Dynamics in the Liver Lobule. Cell Syst 2017;4:277-290.e9. [PMID: 28330614 DOI: 10.1016/j.cels.2017.02.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
3 Giri S, Bader A. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition. Drug Discov Today 2011;16:382-97. [PMID: 21354326 DOI: 10.1016/j.drudis.2011.02.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
4 Enoch SJ, Ellison CM, Schultz TW, Cronin MTD. A review of the electrophilic reaction chemistry involved in covalent protein binding relevant to toxicity. Critical Reviews in Toxicology 2011;41:783-802. [DOI: 10.3109/10408444.2011.598141] [Cited by in Crossref: 120] [Cited by in F6Publishing: 104] [Article Influence: 10.9] [Reference Citation Analysis]
5 Ellison CM, Enoch SJ, Cronin MT. A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity. Expert Opinion on Drug Metabolism & Toxicology 2011;7:1481-95. [DOI: 10.1517/17425255.2011.629186] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
6 Fabian G, Farago N, Feher LZ, Nagy LI, Kulin S, Kitajka K, Bito T, Tubak V, Katona RL, Tiszlavicz L, Puskas LG. High-density real-time PCR-based in vivo toxicogenomic screen to predict organ-specific toxicity. Int J Mol Sci 2011;12:6116-34. [PMID: 22016648 DOI: 10.3390/ijms12096116] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
7 Acikgöz A, Giri S, Bader A. Detection of nanolevel drug metabolites in an organotypic culture of primary human hepatocytes and porcine hepatocytes with special reference to a two-compartment model. Int J Nanomedicine 2012;7:5859-72. [PMID: 23226017 DOI: 10.2147/IJN.S29651] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, Claesson A, Page K, Dolgos H, Kenna JG. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact 2011;192:65-71. [PMID: 21074519 DOI: 10.1016/j.cbi.2010.11.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
9 Fernandez-Checa JC, Bagnaninchi P, Ye H, Sancho-Bru P, Falcon-Perez JM, Royo F, Garcia-Ruiz C, Konu O, Miranda J, Lunov O, Dejneka A, Elfick A, McDonald A, Sullivan GJ, Aithal G, Lucena MI, Andrade RJ, Fromenty B, Krannendonk M, Cubero FJ, Nelson LJ. ADVANCED PRECLINICAL MODELS FOR EVALUATION OF DRUG INDUCED LIVER INJURY - CONSENSUS STATEMENT BY THE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK [PRO-EURO-DILI-NET]. J Hepatol 2021:S0168-8278(21)00441-4. [PMID: 34171436 DOI: 10.1016/j.jhep.2021.06.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mizoi K, Arakawa H, Yano K, Koyama S, Kojima H, Ogihara T. Utility of Three-Dimensional Cultures of Primary Human Hepatocytes (Spheroids) as Pharmacokinetic Models. Biomedicines 2020;8:E374. [PMID: 32977664 DOI: 10.3390/biomedicines8100374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Rowe C, Shaeri M, Large E, Cornforth T, Robinson A, Kostrzewski T, Sison-Young R, Goldring C, Park K, Hughes D. Perfused human hepatocyte microtissues identify reactive metabolite-forming and mitochondria-perturbing hepatotoxins. Toxicol In Vitro 2018;46:29-38. [PMID: 28919358 DOI: 10.1016/j.tiv.2017.09.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
12 Bertrand V, Massy N, Vegas N, Gras V, Chalouhi C, Tavolacci MP, Abadie V. Safety of Cyproheptadine, an Orexigenic Drug. Analysis of the French National Pharmacovigilance Data-Base and Systematic Review. Front Pediatr 2021;9:712413. [PMID: 34676184 DOI: 10.3389/fped.2021.712413] [Reference Citation Analysis]
13 Giri S, Acikgöz A, Pathak P, Gutschker S, Kürsten A, Nieber K, Bader A. Three dimensional cultures of rat liver cells using a natural self-assembling nanoscaffold in a clinically relevant bioreactor for bioartificial liver construction. J Cell Physiol 2012;227:313-27. [PMID: 21437901 DOI: 10.1002/jcp.22738] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
14 Serras AS, Rodrigues JS, Cipriano M, Rodrigues AV, Oliveira NG, Miranda JP. A Critical Perspective on 3D Liver Models for Drug Metabolism and Toxicology Studies. Front Cell Dev Biol 2021;9:626805. [PMID: 33732695 DOI: 10.3389/fcell.2021.626805] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Pomponio G, Savary CC, Parmentier C, Bois F, Guillouzo A, Romanelli L, Richert L, Di Consiglio E, Testai E. In vitro kinetics of amiodarone and its major metabolite in two human liver cell models after acute and repeated treatments. Toxicol In Vitro 2015;30:36-51. [PMID: 25546373 DOI: 10.1016/j.tiv.2014.12.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
16 Ocete Hita E, Martín García J, Giménez Sánchez F, Flores González J, Abril Molina A, Salmerón Escobar J, Ruiz Extremera A. Hepatotoxicidad por fármacos o productos naturales en niños. Anales de Pediatría 2013;78:248-59. [DOI: 10.1016/j.anpedi.2012.06.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
17 Kang D, Hong G, An S, Jang I, Yun WS, Shim JH, Jin S. Bioprinting of Multiscaled Hepatic Lobules within a Highly Vascularized Construct. Small 2020;16:e1905505. [PMID: 32078240 DOI: 10.1002/smll.201905505] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
18 Mizoi K, Hosono M, Kojima H, Ogihara T. Establishment of a primary human hepatocyte spheroid system for evaluating metabolic toxicity using dacarbazine under conditions of CYP1A2 induction. Drug Metabolism and Pharmacokinetics 2020;35:201-6. [DOI: 10.1016/j.dmpk.2019.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Huddam B, Azak A. Hepatitis due to herbal medicine in a peritoneal dialysis patient. Ther Apher Dial 2012;16:606-8. [PMID: 23190524 DOI: 10.1111/j.1744-9987.2012.01093.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
20 Briggs K, Cases M, Heard DJ, Pastor M, Pognan F, Sanz F, Schwab CH, Steger-Hartmann T, Sutter A, Watson DK, Wichard JD. Inroads to predict in vivo toxicology-an introduction to the eTOX Project. Int J Mol Sci 2012;13:3820-46. [PMID: 22489185 DOI: 10.3390/ijms13033820] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
21 Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW Jr, Lightfoot-Dunn R, Hamadeh HK. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010;118:485-500. [PMID: 20829430 DOI: 10.1093/toxsci/kfq269] [Cited by in Crossref: 243] [Cited by in F6Publishing: 205] [Article Influence: 20.3] [Reference Citation Analysis]